stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Total debt
ACADIA Pharmaceuticals Inc.'s total debt at the end of fiscal 2022 was $52.7M, down 6.11% from $56.1M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $48.1M. Over the past ten years it has ranged from $157.0K (fiscal 2016) to $56.1M (fiscal 2021); the current reading is higher than 80% of that period. ACADIA Pharmaceuticals Inc. ranks 132nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $52.7M | (6.11%) |
| FY2021 | $56.1M | 26.24% |
| FY2020 | $44.5M | 598.95% |
| FY2019 | $6.4M | 3,951.59% |
| FY2016 | $157.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $48.1M | (3.36%) |
| Jun 2023 | $49.8M | (3.23%) |
| Mar 2023 | $51.4M | (2.38%) |
| Dec 2022 | $52.7M | (2.00%) |
| 20 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| IRON Disc Medicine, Inc. compare | $59.3M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. | $48.1M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement